Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD

2011679 citationsJournal Articlebronze Open Access

Authors

Claus Vogelmeier · Universitätsklinikum Gießen und Marburg

Bettina Hederer · Boehringer Ingelheim (Egypt)

Thomas Glaab · Boehringer Ingelheim (Egypt)

Hendrik Schmidt · Boehringer Ingelheim (Egypt)

Maureen Rutten‐van Mölken

Kai Michael Beeh · Respiratory Research Institute

Klaus F. Rabe · Leiden University Medical Center

Abstract

These results show that, in patients with moderate-to-very-severe COPD, tiotropium is more effective than salmeterol in preventing exacerbations. (Funded by Boehringer Ingelheim and Pfizer; ClinicalTrials.gov number, NCT00563381.).

Topics & Keywords

Chronic Obstructive Pulmonary Disease (COPD) Research Asthma and respiratory diseases Respiratory Support and Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 364, Issue 12, pp. 1093-1103

DOI: 10.1056/nejmoa1008378

Field-Weighted Citation Impact: 58.24